King & Spalding Advises GE In Solar Technology Partnership With First Solar

Thursday, August 15, 2013 - 15:07

King & Spalding advised GE in its announced technology partnership with First Solar to advance thin-film solar cells and modules. First Solar has acquired GE's global cadmium telluride (CdTe) solar intellectual property portfolio. GE received 1.75 million shares of First Solar common stock as part of this transaction and has agreed to retain the shares for at least three years.

The combination of the two companies' complementary technologies and First Solar's existing manufacturing capabilities are expected to accelerate the development of cadmium telluride (CdTe) solar module performance and improve efficiency at manufacturing scale. In addition, GE Global Research and First Solar R&D will collaborate on future technology development to further advance CdTe solar technology.

The King & Spalding legal team involved in the transaction was led by Atlanta corporate partner William G. Roche and consisted of the following lawyers: Corporate:  E. William Bates, II (partner, New York) and Monika Roth (associate, New York), Intellectual Property:  W. Scott Petty (partner, Atlanta) and James J. Mayberry (counsel, Atlanta).

* * *

King & Spalding advised HanesBrands in its definitive agreement to acquire Maidenform Brands, Inc., for approximately $575 million dollars in cash, on an enterprise-value basis.

The transaction has been unanimously approved by the boards of directors of both companies. The acquisition is subject to Maidenform shareholder approval, regulatory approval and other customary closing conditions. It is expected to close in the fourth quarter of 2013.

The King & Spalding legal team involved in the transaction consisted of the following lawyers: Mergers and Acquisitions: Bill Baxley (partner, Atlanta), Jack Capers (partner, Atlanta), Robert Leclerc (senior associate, New York), Magdeline Drozd (associate, Charlotte) and Nathan Mihalik (associate, Atlanta); Securities: Keith Townsend (partner, Atlanta) and Carrie Ratliff (associate, Atlanta); Litigation: Michael Smith (partner, Atlanta); Antitrust: Jeffrey Spigel (partner, Washington) and John Carroll (senior associate, Washington); Benefits: Eleanor Banister (partner, Atlanta), Mark Kelly (counsel, Atlanta) and Ryan Gorman (associate, Atlanta); and Tax: John Sweet (partner, New York).

* * *

King & Spalding added David J. Farber, a life sciences and healthcare regulatory litigation specialist, as a partner in its Food and Drug Administration, life sciences and healthcare practices in the firm’s Washington, DC, office.

“David is one of the top practitioners in life sciences and healthcare law, and we are delighted to welcome him to our firm,” said King & Spalding FDA and life sciences practice group leader Mark S. Brown. “His regulatory experience complements our capabilities in those areas, and we believe his unique talents will be of great benefit to our clients.”

Mr. Farber has a strong litigation background in the life sciences and health care sectors and is a leading national expert on Medicare secondary payor matters. His practice also encompasses government advocacy and regulatory counseling. He works regularly on Capitol Hill and with key regulatory agencies, particularly the Centers for Medicare & Medicaid Services and U.S.  Food and Drug Administration on legislative and regulatory advocacy and counseling matters. Farber received a J.D. degree from Georgetown University Law Center and a B.A. degree from New York University.

* * *

In the 2013 edition of LMG Life Sciences, 10 King & Spalding lawyer have been identified as “life sciences stars.” Published by Legal Media Group in association with Benchmark: Litigation, Managing IP, and IFLR, LMG Life Sciences aims to recognize the “highest profile, most sought-after and best-attorneys working in life sciences.”

At the practice level, King & Spalding was again "highly recommended" by LMG Life Sciences in the area of FDA-medical device regulatory work. The firm also retained its ‘recommended’ status for both government investigations/ fraud & abuse and product liability matters on behalf of life sciences clients this year.

LMG Life Sciences bases its research on online surveys and interviews with lawyers across the United States. Its researchers also spoke to clients and leading lawyers within the industry and reviewed public information to inform their decisions.

The 2013 edition of LMG Life Sciences included the following King & Spalding lawyers:

Edward M. Basile (Regulatory); Andy T. Bayman (Non-IP Litigation and Enforcement); Mark S. Brown (Regulatory); Gina M. Cavalier (Non-IP Litigation and Enforcement); Frederick H. Degnan (Regulatory); Mark A. Jensen (Non-IP Litigation and Enforcement); Christina M. Markus (Regulatory); John D. Shakow (Regulatory); J. Sedwick Sollers (Non-IP Litigation and Enforcement); and Chilton Davis Varner (Non-IP Litigation and Enforcement).

King & Spalding’s FDA & Life Sciences practice focuses on representing pharmaceutical, medical device, biotechnology and other healthcare technology companies, as well as food manufacturers, in a wide range of regulatory, compliance, policy, and litigation matters. The group provides sophisticated counseling and advice to more than 100 drug and device manufacturers and others in the healthcare technology sector, including nine of the 25 largest pharmaceutical manufacturers, and 18 of the 25 largest device manufacturers.